Compare Abbott India with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs PANACEA BIOTECH - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA PANACEA BIOTECH ABBOTT INDIA/
PANACEA BIOTECH
 
P/E (TTM) x 48.6 13.2 368.3% View Chart
P/BV x 15.7 5.1 305.6% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 ABBOTT INDIA   PANACEA BIOTECH
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
PANACEA BIOTECH
Mar-19
ABBOTT INDIA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs8,834354 2,498.3%   
Low Rs5,458138 3,949.0%   
Sales per share (Unadj.) Rs1,731.174.6 2,321.7%  
Earnings per share (Unadj.) Rs211.96.7 3,172.8%  
Cash flow per share (Unadj.) Rs219.915.5 1,419.0%  
Dividends per share (Unadj.) Rs65.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs945.257.2 1,652.2%  
Shares outstanding (eoy) m21.2561.25 34.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.3 125.2%   
Avg P/E ratio x33.736.8 91.6%  
P/CF ratio (eoy) x32.515.9 204.8%  
Price / Book Value ratio x7.64.3 175.9%  
Dividend payout %30.70-   
Avg Mkt Cap Rs m151,84815,061 1,008.2%   
No. of employees `0003.52.3 150.6%   
Total wages/salary Rs m4,3561,471 296.2%   
Avg. sales/employee Rs Th10,555.51,973.6 534.8%   
Avg. wages/employee Rs Th1,249.9635.6 196.6%   
Avg. net profit/employee Rs Th1,292.2176.8 730.9%   
INCOME DATA
Net Sales Rs m36,7864,567 805.5%  
Other income Rs m1,13345 2,528.8%   
Total revenues Rs m37,9194,612 822.2%   
Gross profit Rs m6,0472,030 297.9%  
Depreciation Rs m169540 31.3%   
Interest Rs m231,048 2.1%   
Profit before tax Rs m6,989486 1,437.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,48577 3,223.3%   
Profit after tax Rs m4,503409 1,100.8%  
Gross profit margin %16.444.4 37.0%  
Effective tax rate %35.615.9 224.3%   
Net profit margin %12.29.0 136.7%  
BALANCE SHEET DATA
Current assets Rs m27,6102,415 1,143.5%   
Current liabilities Rs m8,5699,077 94.4%   
Net working cap to sales %51.8-145.9 -35.5%  
Current ratio x3.20.3 1,211.4%  
Inventory Days Days6065 92.5%  
Debtors Days Days2771 38.6%  
Net fixed assets Rs m1,0578,333 12.7%   
Share capital Rs m21361 346.7%   
"Free" reserves Rs m19,8733,443 577.3%   
Net worth Rs m20,0863,504 573.2%   
Long term debt Rs m0461 0.0%   
Total assets Rs m29,40913,755 213.8%  
Interest coverage x311.61.5 21,287.1%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.30.3 376.7%   
Return on assets %15.410.6 145.2%  
Return on equity %22.411.7 192.0%  
Return on capital %34.938.7 90.2%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m3691,203 30.7%   
Fx outflow Rs m4,918467 1,054.0%   
Net fx Rs m-4,549736 -617.8%   
CASH FLOW
From Operations Rs m4,9911,049 475.9%  
From Investments Rs m-2,570-54 4,803.7%  
From Financial Activity Rs m-1,428-1,011 141.2%  
Net Cashflow Rs m993-20 -5,042.1%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.6 1,316.7%  
FIIs % 0.1 1.3 7.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 23.6 72.5%  
Shareholders   18,270 10,259 178.1%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ORCHID PHARMA  WYETH  TORRENT PHARMA  SUVEN LIFE SCIENCES  CIPLA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Apr 20, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - GLENMARK PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS